Literature DB >> 29954234

Modified ARCA analogs providing enhanced translational properties of capped mRNAs.

Ilona Kocmik1, Karolina Piecyk1, Magdalena Rudzinska2, Anna Niedzwiecka3, Edward Darzynkiewicz2,4, Renata Grzela2, Marzena Jankowska-Anyszka1.   

Abstract

Nowadays gene manipulation techniques ("DNA therapy") undergo progressive development and become widely used in industry and medicine. Since new advances in mRNA technologies are capable for obtaining particles with increased stability and translational efficiency, RNA become an attractive alternative for advancement of DNA therapy. For the past years studies have been conducted to explore different modification in mRNA cap structure and its effect on RNA properties. Recently we have shown that modification of the cap structure at the N2 position of 7-methylguanosine leads to an enhancement in translation inhibition. Currently, we have decided to exploit translational properties of mRNA capped with the ARCA (anti-reversed cap) analogs modified within N2 position of purine moiety s. We designed and synthesized three new dinucleotide cap analogs and investigated them in the rabbit reticulocyte lysate (RRL) and the human embryonic kidney derived HEK293 cell line, in vitro translational model systems. The obtained data indicate that, in both translational assays, the cap analogs synthesized by us when incorporated into mRNA improved its translational properties compared to the ARCA capped transcripts. Furthermore, the introduced modifications enhanced stability of the capped transcripts in HEK293 cells, which become higher compared to that of the transcripts capped with regular cap or with ARCA. Additionally one of the synthesized cap analogs revealed strong translation inhibition potency in RRL system, with IC50 value 1.7 µM.

Entities:  

Keywords:  ARCA cap; Cap; N2 guanosine modification; RNA therapy; cap-dependent translation

Mesh:

Substances:

Year:  2018        PMID: 29954234      PMCID: PMC6133335          DOI: 10.1080/15384101.2018.1486164

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  36 in total

1.  Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of cap-dependent translation.

Authors:  Joanna Kowalska; Maciej Lukaszewicz; Joanna Zuberek; Marcin Ziemniak; Edward Darzynkiewicz; Jacek Jemielity
Journal:  Bioorg Med Chem Lett       Date:  2009-02-21       Impact factor: 2.823

Review 2.  Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond.

Authors:  Britta Vallazza; Sebastian Petri; Marco A Poleganov; Florian Eberle; Andreas N Kuhn; Ugur Sahin
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-06-09       Impact factor: 9.957

3.  Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation.

Authors:  A Cai; M Jankowska-Anyszka; A Centers; L Chlebicka; J Stepinski; R Stolarski; E Darzynkiewicz; R E Rhoads
Journal:  Biochemistry       Date:  1999-06-29       Impact factor: 3.162

4.  Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.

Authors:  Robert E Rhoads
Journal:  Methods Mol Biol       Date:  2016

5.  Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.

Authors:  A N Kuhn; M Diken; S Kreiter; A Selmi; J Kowalska; J Jemielity; E Darzynkiewicz; C Huber; O Türeci; U Sahin
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

Review 6.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

Review 7.  eIF4F: a retrospective.

Authors:  William C Merrick
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

8.  Reverse 5' caps in RNAs made in vitro by phage RNA polymerases.

Authors:  A E Pasquinelli; J E Dahlberg; E Lund
Journal:  RNA       Date:  1995-11       Impact factor: 4.942

9.  Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP.

Authors:  Yan Jia; Ting-Lan Chiu; Elizabeth A Amin; Vitaly Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  Eur J Med Chem       Date:  2009-12-06       Impact factor: 6.514

10.  Structural changes of eIF4E upon binding to the mRNA 5' monomethylguanosine and trimethylguanosine Cap.

Authors:  Izabela Rutkowska-Wlodarczyk; Janusz Stepinski; Michal Dadlez; Edward Darzynkiewicz; Ryszard Stolarski; Anna Niedzwiecka
Journal:  Biochemistry       Date:  2008-01-26       Impact factor: 3.162

View more
  8 in total

Review 1.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

Review 2.  mRNA as a Therapeutics: Understanding mRNA Vaccines.

Authors:  Ferdi Oğuz; Harika Atmaca
Journal:  Adv Pharm Bull       Date:  2021-05-16

Review 3.  The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.

Authors:  Miroslaw Janowski; Anna Andrzejewska
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

Review 4.  The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Cancer Treat Rev       Date:  2022-05-05       Impact factor: 13.608

Review 5.  Opportunities and Challenges in the Delivery of mRNA-based Vaccines.

Authors:  Abishek Wadhwa; Anas Aljabbari; Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

Review 6.  Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines.

Authors:  Muthian Shanmugasundaram; Annamalai Senthilvelan; Anilkumar R Kore
Journal:  Chem Rec       Date:  2022-04-14       Impact factor: 6.935

Review 7.  Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma.

Authors:  Xiangjun Tang; Shenqi Zhang; Rui Fu; Li Zhang; Kuanming Huang; Hao Peng; Longjun Dai; Qianxue Chen
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

8.  Decapping Scavenger Enzyme Activity toward N2-Substituted 5' End mRNA Cap Analogues.

Authors:  Paulina Pietrow; Aleksandra Ferenc-Mrozek; Karolina Piecyk; Elzbieta Bojarska; Edward Darzynkiewicz; Marzena Jankowska-Anyszka
Journal:  ACS Omega       Date:  2019-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.